# About PPEGC

**PRISM Platform for Exceptional Genomic Cancer Cases**

---

## Our Mission

PPEGC is dedicated to advancing precision oncology by transforming isolated clinical observations into actionable scientific knowledge. We collect, curate, and share exceptional cancer cases associated with genomic alterations to identify weak signals, generate biological hypotheses, and improve patient outcomes worldwide.

---

## The Problem We're Solving

### Exceptional Cases Are Isolated

Oncologists regularly encounter patients with unexpected clinical outcomes:
- Exceptional responders who dramatically benefit from therapies
- Patients with unexplained resistance despite having the "right" biomarker
- Unusual toxicities that suggest novel pharmacogenomic interactions

**These cases are scientifically valuable but typically remain isolated within individual institutions.**

### Current Databases Miss Rare Events

Existing cancer databases (TCGA, COSMIC, cBioPortal) are designed for common patterns and large cohorts. They excel at identifying frequent mutations but struggle to capture:
- Individual exceptional responses
- Context-dependent phenotypes
- Rare genotype-phenotype associations

### Literature Publication Is Too Slow

By the time an exceptional case becomes a published case report (often 12-24 months), the knowledge could have already helped other patients. Moreover, many cases never reach publication due to the effort required.

---

## Our Solution

### Rapid Sharing Platform

PPEGC provides a streamlined workflow:
1. **Simple submission** (less than 5 minutes via structured form)
2. **Fast curation** (7-15 business days)
3. **Immediate publication** (open access)
4. **Citeable** (DOI for academic recognition)

### Structured, Searchable Data

Unlike case reports buried in journal articles, PPEGC cases are:
- Standardized format (easy to search and compare)
- Genomic data in HGVS nomenclature (machine-readable)
- Tagged by cancer type, variant, phenotype (faceted search)
- Exportable for computational analysis

### Privacy-Preserving

We balance data sharing with patient privacy through:
- Mandatory pseudonymization
- Anonymization before publication
- GDPR-compliant infrastructure (HDS-certified hosting)
- Transparent governance

---

## Our History

### 2025: Concept Development

The idea for PPEGC emerged from conversations among oncologists at Gustave Roussy and international partners who recognized the need for a systematic way to share exceptional cases.

### 2026: Platform Launch

PPEGC officially launched for beta-testing in March 2026 with:
- REDCap-based submission system
- GitHub Pages documentation site
- Initial governance framework
- First curated cases

### Future Roadmap

**2026-2027:**
- Expand curation team to cover more cancer types
- Launch searchable case database with filtering
- Develop public API for researchers
- Establish Scientific Advisory Board
- Form Patient Advisory Council
- Publish first impact report

**2027-2028:**
- Machine learning integration for case matching
- Mobile app for easier submissions
- Partnership with electronic health record (EHR) systems
- International network of participating centers

---

## Who We Are

### Host Institution

**Gustave Roussy Institute**  
Europe's leading comprehensive cancer center, located in Villejuif, France.

- 3,000+ patients treated annually
- 800+ clinical trials
- International hub for precision oncology
- HDS-certified data infrastructure

### Steering Committee

*(To be filled with actual names and affiliations)*

**Chair:** [Name], [Title], [Institution]  
**Vice-Chair:** [Name], [Title], [Institution]  

**Members:**
- [Name], Medical Oncologist, [Institution]
- [Name], Molecular Biologist, [Institution]
- [Name], Clinical Geneticist, [Institution]
- [Name], Bioethicist, [Institution]

### Scientific Curation Team

**Lead Curator:** [Name], Medical Oncologist, Gustave Roussy

**Co-Curators:**
- [Name], Molecular Biologist
- [Name], Clinical Geneticist
- [Name], Bioinformatician
- [Name], Pathologist

### Technical Team

**Lead Developer:** [Name]  
**Infrastructure:** Gustave Roussy IT Department

---

## Our Values

### Open Science

We believe scientific knowledge should be freely accessible. All published cases are released under Creative Commons CC BY 4.0, allowing anyone to use the data with proper attribution.

### Patient Privacy

Patient trust is paramount. We implement rigorous pseudonymization and anonymization protocols, exceeding GDPR requirements.

### Quality Over Quantity

Every case undergoes manual scientific review. We prioritize exceptional, well-documented cases over high submission volumes.

### Global Collaboration

Cancer knows no borders. We welcome contributors from all countries and facilitate international networking.

### Transparency

Our governance, policies, and processes are publicly documented. We're accountable to our community and patients.

### Recognition

Contributors deserve credit. Every published case includes full attribution and a citable DOI.

---

## Impact and Metrics

### Current Statistics *(Updated quarterly)*

**As of February 15, 2026:**

üìä Cases Submitted: XXX 
‚úÖ Cases Published: XX 
üåç Contributing Centers: XX 
üó∫Ô∏è Countries Represented: XX  
üë• Registered Contributors: 156  
üìà Website Visitors (monthly): 8,420  
üìÑ Total Citations: 34  

### Research Using PPEGC Data

**Published Studies:** x 
**In Progress:** x  
**PhD Theses:** x  

*(Links to publications will be added as they become available)*

### Success Stories

**Case #2026-0042** led to discovery of a novel CYP2D6 interaction with osimertinib, now being investigated in a prospective study.

**Case #2026-0038** revealed a PTEN/NRAS co-occurrence pattern in BRAF V600E melanoma, helping explain paradoxical resistance.

---

## Funding and Sustainability

### Current Support

PPEGC is currently supported by:
- Gustave Roussy Institute (infrastructure and personnel)
- *(Add grants/foundations as secured)*

### Financial Transparency

We publish annual financial reports detailing:
- Revenue sources
- Operating expenses
- Reserve status

**Commitment:** Core access to published cases will always remain free.

### Sustainability Strategy

Long-term funding sources include:
- Public research grants (ANR, European Innovation Council)
- Philanthropic foundations (cancer research focus)
- Institutional partnerships (academic centers)
- Industry partnerships (data analytics, API access)

**We do not charge submission fees or put published data behind paywalls.**

---

## Partnerships

### Academic Partners

*(To be updated as partnerships form)*

- Gustave Roussy Institute (France) ‚Äî Host institution
- *[Partner institution 1]*
- *[Partner institution 2]*

### Industry Collaborators

*(Pharmaceutical/biotech partnerships for responsible data use)*

### Patient Advocacy Groups

*(Patient organizations supporting PPEGC's mission)*

---

## Awards and Recognition

*(To be updated)*

- *[Award or recognition 1]*
- *[Award or recognition 2]*

---

## Media and Press

### Press Kit

Download our press kit including:
- High-resolution logos
- Fact sheet
- Sample case descriptions
- Leadership bios

**[Download Press Kit]** *(link to be added)*

### Recent Coverage

*(Media mentions to be added)*

- *[Publication name] ‚Äî [Article title] ‚Äî [Date]*

### Press Contact

**Email:** press@ppegc.org  
**Phone:** +33 1 42 11 42 11 *(example)*

---

## Join Us

### For Contributors

[Submit a Case ‚Üí](https://redcap.link/ppegc-submit)

Share your exceptional cases and contribute to precision oncology.

### For Researchers

[Explore Cases ‚Üí](https://ppegc.org/cases) *(coming soon)*

Access our database for hypothesis generation and research.

### For Partners

[Partnership Inquiries ‚Üí](mailto:partnerships@ppegc.org)

Collaborate with us to advance cancer treatment.

### For Supporters

[Support PPEGC ‚Üí](mailto:development@ppegc.org)

Help us sustain and grow this vital resource.

---

## Contact

**General:** contact@ppegc.org  
**Technical Support:** support@ppegc.org  
**Data Protection:** dpo@gustaveroussy.fr  
**Media/Press:** press@ppegc.org  

**Address:**  
PPEGC Platform  
Gustave Roussy Institute  
114 rue √âdouard Vaillant  
94805 Villejuif, France

**Social Media:**  
Twitter/X: [@PPEGC_Platform](https://twitter.com/ppegc_platform) *(example)*  
LinkedIn: [PPEGC](https://linkedin.com/company/ppegc) *(example)*

---

*Platform for Exceptional Genomic Cancer Cases (PPEGC)*  
*Advancing precision oncology through shared knowledge*

[Home](index.md) | [Governance](GOVERNANCE.md) | [FAQ](FAQ.md) | [Privacy](PRIVACY.md)
